You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

31 Results
Guidelines and Advice
Status: Current
ID: 4-16
Version: 3
May 2025
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®, Filra™
Sep 2025
Drug
Other Name(s): Efudex® Cream , IV generic brands available
Jan 2026
Drug
Other Name(s): Euflex®
Aug 2025
Drug
Other Name(s): Faslodex®
Aug 2025
Drug
Other Name(s): Camptosar®
Sep 2025
Drug
Other Name(s): Imbruvica®
Jan 2026
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Aug 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Cetuximab with Irinotecan - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Aug 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For relapsed and refractory mantle cell lymphoma, based on criteria
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), based on criteria
Jan 2026

Pages